Lutikizumab Offers Relief for Refractory HS



Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/lutikizumab-offers-relief-moderate-severe-hidradenitis-2026a10008dn?src=rss

Author :

Publish date : 2026-03-19 07:45:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version